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Abstract: Background: Recent evidence supports a role of probiotics in preventing necrotizing
enterocolitis (NEC) in preterm infants. Methods: A systematic review and network meta-analysis of
randomized controlled trials (RCTs) on the role of probiotics in preventing NEC in preterm infants,
focusing on the differential effect of type of feeding, was performed following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model
was used; a subgroup analysis on exclusively human milk (HM)-fed infants vs. infants receiving
formula (alone or with HM) was performed. Results: Fifty-one trials were included (10,664 infants,
29 probiotic interventions); 31 studies (19 different probiotic regimens) were suitable for subgroup
analysis according to feeding. In the overall analysis, Lactobacillus acidophilus LB revealed the most
promising effect for reducing NEC risk (odds ratio (OR), 0.03; 95% credible intervals (CrIs), 0.00–0.21).
The subgroup analysis showed that Bifidobacterium lactis Bb-12/B94 was associated with a reduced
risk of NEC stage ≥2 in both feeding type populations, with a discrepancy in the relative effect
size in favour of exclusively HM-fed infants (OR 0.04; 95% CrIs <0.01–0.49 vs. OR 0.32; 95% CrIs
0.10–0.36). Conclusions: B. lactis Bb-12/B94 could reduce NEC risk with a different size effect
according to feeding type. Of note, most probiotic strains are evaluated in few trials and relatively
small populations, and outcome data according to feeding type are not available for all RCTs. Further
trials are needed to confirm the present findings.
Keywords: necrotizing enterocolitis; preterm infants; probiotics; systematic review; network meta-
analysis
1. Introduction
Necrotizing enterocolitis (NEC) is a significant cause of morbidity and mortality in
preterm infants with low birth weight (BW) and gestational age (GA). Recent meta-analyses
estimated that 7% of low BW infants in neonatal intensive care units are likely to develop
NEC [1]; mortality varies from 10% to 30% and has remained largely unchanged since the
initial disease description several decades ago.
Evidence of the protective role of human milk (HM) against NEC in preterm infants
is robust [2–5]. In recent years, the role of probiotic administration in preventing NEC
has been also investigated through observational studies and randomized controlled trials
(RCTs), whose results have been summarized in numerous systematic reviews and meta-
analyses [6–14]. However, these studies have failed to provide clinically meaningful
recommendations [15].
To overcome traditional meta-analytical approach limitations, van den Akker et al.
recently performed a strain-specific network meta-analysis (NMA) on probiotics’ effects
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in reducing mortality and morbidity in preterm infants [16]. Following updated evidence
provided by this study, in 2020, the European Society of Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) published a position paper [17] aimed at providing
clinicians with recommendations on probiotic strains with proven efficacy and safety in
preterm infants. In addition, a recent NMA [18] focused on the differential performance
of multi- vs. single-strain probiotics in reducing mortality and morbidity in preterm
infants [16].
Beyond strain specificity, current scientific literature about probiotic use in preterm
infants lacks detailed information about potential significant moderators, including type
of feeding [15]. It has been suggested that probiotics might be more effective in infants
fed HM rather than formula milk (FM), with nutrition and supplemental probiotics acting
together in preterm infants’ guts, leading to a differential effect of exogenous bacteria
depending on the type of feeding [12,19,20].
Hence, we performed an updated systematic review and NMA investigating probi-
otics’ role in preventing NEC in preterm infants and focused on the potential moderation
effect of feeding type.
2. Materials and Methods
2.1. Study Design, Search Strategy and Selection Criteria
The study protocol was designed by the authors AA, IB, DG and JL. A systematic
review of published studies reporting the use of probiotics for NEC prevention in preterm
infants, according to type of feeding, and a Bayesian NMA were performed in accordance
with the PRISMA Extension Statement for Reporting of Systematic Reviews incorporating
NMA—Supplemental Section A [21].
Criteria for inclusion in the systematic review and NMA were the following: RCTs
or quasi-RCTs involving preterm infants (gestational age <37 weeks) and reporting on
NEC (any stage, according to the modified Bell’s staging criteria); enteral administration
of any probiotic starting within one month of age; probiotic nomenclature available at
least at a species level. Studies comparing probiotic treatment against placebo, usual care
or head-to-head with a different probiotic regimen, including single- and multiple-strain
probiotics, were considered eligible.
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and the Cochrane Library (http:
//www.cochranelibrary.com/) were interrogated for studies published before 7th January
2020 (Supplemental Section B). The review was restricted to studies involving human
subjects; no language restriction was applied.
AA, IB and DP independently performed the literature search. Studies potentially
eligible according to the inclusion criteria were identified from the abstracts; full texts of
relevant studies were assessed for inclusion and their reference lists were searched for
additional studies. Reference lists of previously published meta-analyses were screened to
identify further eligible studies. Inconsistency was resolved through consensus.
2.2. Study Selection and Data Extraction
Study details (population, characteristics of probiotic and placebo, type of feeding
and outcome assessment) were evaluated independently by IB, DP and AA. Data were
extracted using standardized forms. Missing or incomplete data, including separate data
for NEC incidence in infants receiving probiotics vs. controls according to type of feeding
(exclusive HM vs. exclusive formula or mixed feeding), were requested by contacting the
corresponding authors. If the corresponding author was unable to provide these data or
did not reply to the email, the paper was excluded from the meta-analysis.
According to the International Scientific Association of Probiotics and Prebiotics and
the statement by the Food and Agriculture Organization of the United Nations and the
World Health Organization for probiotics [22], probiotic products were identified at the
highest taxonomic level whenever possible and, to the best of our knowledge, we adhered
to the latest nomenclature and taxonomic description. In this respect, Lactobacillus sporo-
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genes was designated as Bacillus coagulans, Bifidobacterium infantis 35,624 as Bifidobacterium
longum 35,624 and Bifidobacterium bifidum Bb-12 as Bifidobacterium lactis Bb-12. Since Bi-
fidobacterium lactis Bb-12 and Bifidobacterium lactis B94 share many characteristics, these
strains were analyzed together. When strain level was not available in the original reports,
whenever possible, it was obtained through Internet searches (i.e., on probiotic manufac-
turers’ websites) on available product names and technical sheets or previously published
meta-analyses.
2.3. Quality Assessment and Risk of Bias
Quality assessment and risk of bias critical appraisals were conducted using the
Cochrane risk of bias tool for RCTs [23]. IB and DP assessed each study separately, with
conflicts resolved through consensus. Funnel plots were used to investigate publication
bias. In addition, assessment of body of evidence quality using the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) working group approach
was performed by DG [24].
All authors had access to the study data and reviewed and approved the final
manuscript.
2.4. Statistical Analysis
We conducted a random-effects Bayesian NMA to synthesize all available evidence on
probiotics for NEC prevention in preterm infants and to obtain a comprehensive ranking of
all available probiotic treatments. Given that most treatments were evaluated in a limited
number of RCTs, to reduce the sparsity of the network and potential model instability,
we chose to pool single treatments into categories according to single treatments’ charac-
teristics. At first, multi-genus probiotics were included in the same treatment category;
we then performed a secondary NMA on main grouped treatments to rank their efficacy.
Individual probiotic interventions and corresponding treatment categories are summarized
in Supplemental Tables S1 and S2.
Network structure was explored using network diagrams. Summary effect sizes were
expressed as posterior medians of odds ratios (ORs) with 95% credible intervals (CrIs). All
pairwise comparisons were summarized in a “league table”, a square matrix containing all
information about relative efficacy (ORs) and their uncertainty (95% CrIs) for all possible
pairs of interventions. Forest plots were generated to inspect the relative effects of each
treatment compared to placebos. Surface under the cumulative ranking curve (SUCRA)
was calculated to rank the efficacy of the various treatments [25]. Furthermore, NMA
was also performed according to the frequentist approach and P-scores were calculated to
compare treatments. Inconsistency was assessed using unrelated mean-effects models.
We evaluated whether infant feeding could act as an effect modifier across treatment
comparisons by carrying out a subgroup analysis on exclusively HM-fed infants vs. in-
fants receiving formula (alone or in addition to HM), and by informally comparing the
magnitudes of effects and rankings.
We fit the NMA model using WinBUGS 1.4.3 [26] and visualized results using Stata
15 software (StataCorp. 2017. Stata Statistical Software: Release 15. College Station,
TX: StataCorp LLC) and the Microsoft Excel-based tool NetMetaXL. All analyses were
duplicated in the frequentist framework using the netmeta package in R [27]. Classic
pairwise forest plots were generated using RevMan (version 5.4). A detailed description of
the statistical methods is provided in Appendix A.
3. Results
3.1. Search Results and Study Characteristics
The number of potentially relevant papers identified through the literature search
was 715 (556 in MEDLINE via PubMed and 159 in Cochrane Library); 19 additional trials
were retrieved by hand searching. After excluding duplicates, 648 records were screened,
of which 576 were excluded due to not meeting the inclusion criteria. Finally, 51 studies
Nutrients 2021, 13, 192 4 of 14
assessing the effects of 29 different probiotic interventions were eligible for inclusion in the
systematic review and primary NMA [28–78] (Figure 1).
Nutrients 2021, 13, x FOR PEER REVIEW 4 of 14 
 
 
3.1. Search Results and Study Characteristics 
The number of potentially relevant papers identified through the literature search 
was 715 (556 in MEDLINE via PubMed and 159 in Cochrane Library); 19 additional trials 
were retrieved by hand searching. After excluding duplicates, 648 records were screened, 
of which 576 were excluded due to not meeting the inclusion criteria. Finally, 51 studies 
assessing the effects of 29 different probiotic interventions were eligible for inclusion in 




Figure 1. Flow diagram of search strategy and study selection. 
Only 18 studies reported NEC according to feeding type during the study period: ten 
studies reported NEC in exclusively HM-fed infants [29,33,40,51,53,62,64,70,74,76], either 
the mother’s own (MOM) or donor human milk (DHM), five studies included exclusively 
formula-fed infants [34,36,55,69,77], one study included infants who received HM plus 
FM [46] and two studies reported outcome according to different feeding types [37,57]. 
Figure 1. Flow diagram of search strategy and study selection.
Only 18 studies reported NEC according to feeding type during the study period: ten
studies reported NEC in exclusively HM-fed infants [29,33,40,51,53,62,64,70,74,76], either
the mother’s own (MOM) or donor human milk (DHM), five studies included exclusively
formula-fed infants [34,36,55,69,77], one study included infants who received HM plus
FM [46] and two studies reported outcome according to different feeding types [37,57].
Separate data according to type of feeding were provided by e-mail for 13 of these stud-
ies [28,39,44,45,48,56,58,63,66–68,72,75]. Thus, 31 studies assessing the effects of 19 differ-
ent probiotic interventions were suitable for inclusion in the subgroup NMA focusing on
feeding.
Details of the included studies and NEC rates in the probiotic and in the placebo/control
groups are reported in Table S1. Identified probiotic strains and corresponding treatment
groups are summarized in Supplemental Tables S1 and S2. Not all probiotic strains were
retrieved.
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3.2. Quality Assessment and Risk of Bias
The quality assessment of the studies included in the NMA is shown in Supplemental
Figure S1. Few included studies were at low risk of bias on all components. Supplemental
Table S3 also shows the body of evidence assessment using the GRADE working group
approach. A visual inspection of the evidence base by means of funnel plot (Supplemental
Figure S2) did not show any clear publication bias.
3.3. Probiotics and NEC: Overall Population
Figure 2 shows the network graph comparing probiotic categories for the prevention
of NEC in the overall population, regardless of type of feeding. The network geometry is
based on 13 treatment categories, assessed in 42 studies, versus the common comparator
placebo, including 9658 patients. There was only one trial performing a direct head-to-head
comparison between two probiotic treatments [44]. Nine studies, including 1006 infants,
were initially excluded as there were zero events in both the placebo and intervention
groups (Supplemental Table S2) [43,50,57,60,71,72,75,77,78].
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Figure 2. Network diagram. The area of the nodes is based on the total number of patients for
each treatment among all trials. The thickness of the lines represents the total number of studies
comparing the two treatments/nodes. B.b: B. breve BBG YIT4010, B. breve BBG-001, B. breve M-16V;
B.la: Bifidobacterium lactis Bb-12 OR B94; B.lBB536: B. longum BB536; L.r: Lactobacillus reuteri DSM
17938, L. reuteri ATCC 55730; LGG53103: L. rhamnosus GG ATCC 53103 L.a: L. a idophilu LB; LCR35:
L. casei var. rhamnosus (LCR 35); Ba.co: Bacillus coagulans (L. sporogenes); Ba.c: Ba. clausii (four strains);
Sa.b: Saccharomyces boulardii CNCM I-745, Sa. boulardii CNCMI-3799; B.MS: B. lactis Bb-12 + B. longum
BB536; B.l + LGG: B. longum 35,624 + L. rhamnosus GG, B. longum BB536 + L. rhamnosus GG; MG:
multi-genus probiotic group.
According to SUCRA values of each treatment group (Figure 3A), Lactobacillus aci-
dophilus LB ranked as the best supplementation option for preventing NEC in preterm
infants; other high-ranking options were B. lactis Bb-12 OR B94, B. longum BB536, L. reuteri
DSM 17938/ATCC 55,730 and the multi-genus probiotic group. These findings are consis-
tent with the rankograms illustrated in Supplemental Figure S3.
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Fig re 3. ar chart of surface under the cumulative ranking curve (SUCRA) scores (A) and forest plot of relative effect sizes
compared to placebo (B) for each treatment under study.
However, as shown in Figure 3B, the odds ratio of B. longum BB536 showed a wide CrI
including one (zero on the log scale). O the other ha d, the ORs and CrIs of Lactobacillus
acidophilus LB, B. lactis Bb-12 OR B94, L. re teri DSM 17938/ATCC 55,730 and the multi-
genus group confi ed that these treatments were associated with a reduced risk of all
stages of NEC. A league table with all pairwise comparisons between the competing
treatments (ORs with 95% CrIs) is shown in Supplemental Figure S4. No evidence of
inconsistency in the network was documented (Supple ental Figure S5). Results of the
subgroup NMA conducted to rank single treatments included in the multi-genus probiotic
group are shown in Supplemental Figure S6.
The main findings of the Bayesian analysis agreed with results from the frequentist
approach, where a similar treatment ranking according to the P-scores was found (Supple-
mental Table S4 and Figure S7). The results proved to be robust also when trials with no
events in both arms were included in the analysis (Supplemental Figure S8).
3.4. Probiotic and NEC According to Feeding Type
An NMA focused on feeding type was also performed, including only studies for
which outcome data according to feeding type were available. The overall network ge-
ometry was based on 13 treatment categories, assessed in 27 studies, versus the common
comparator placebo, including 4173 patients. Four double-zero trials, including 378 infants,
were initially excluded from the primary Bayesian meta-analysis [57,72,75,77], as well as an
additional treatment investigated by Oshiro and colleagues (B.bBBG, B. breve BBG-001) [57].
Lactobacillus acidophilus LB showed the highest SUCRA value, followed by B. longum
BB536, B. breve M-16V, L. reuteri 17938, B. lactis Bb-12 OR B94 and the multi-genus group
(Figure 4A). However, as shown in Figure 3B, the ORs of Lactobacillus acidophilus LB, B.
longum BB536 and B. breve M-16V had wide CrIs that included one (zero on the log scale).
On the other hand, the distributions of the ORs of L. reuteri 17938, B. lactis Bb-12 OR B94
and the multi-genus group indicated that these treatments were associated with a reduced
risk of NEC (Figure 4B). The results proved to be robust also when evidence from trials
with no events in both arms was incorporated (Supplemental Figure S9).
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to placebo (Figure 5B), only B. lactis Bb-12 OR B94, based on one trial [39] with 1 infants,
L. reuteri DSM17938, based on two trials [67,76] with 194 infants, and the multi-genus
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B. longu R00175 + L. helveticus R0052 + L. rha nosus R0011 + Sa. boulardii C C -I-1079
(based on t o RCTs [29,68] ith 254 infants) and B. infantis ATCC15697 + L. acidophilus
ATCC4356 (based on one RCT [51] with 367 infants) indicated that these treatments were
associated with a reduced risk of stage ≥ 2 NEC in exclusively HM-fed preterm infants.
Among the treatments evaluated in non-exclusively HM-fed preterm infants (Figure 5A–B)
B. longum 35,624 + L. rhamnosus GG had the best SUCRA values; other efficacious options
appeared to be B. longum BB536, L. reuteri DSM17938, the multi-genus probiotic group, B. lactis
Bb-12 OR B94 and L. rhamnosus LGG ATTC53103. However, the ORs of B. longum 35,624 + L.
rhamnosus GG, L. rhamnosus LGG ATTC 53103, the multi-genus probiotic group and B. longum
BB536 showed a wide CrI that included one (zero on the log scale). On the other hand, the
ORs of B. lactis Bb-12 OR B94, based on four trials [39,45,55,69] with 355 infants, and L. reuteri
DSM17938, based on four RCTs [36,46,48,56] with 631 infants, indicate that these treatments
were associated with a reduced risk of any-stage NEC in non-exclusively HM-fed preterm
infants. Only B. lactis Bb-12 OR B94 was significantly associated with a reduced risk of stage ≥
2 NEC, since one RCT evaluating L. reuteri DSM17938 also included stage 1 NEC [46].
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options appeared to be B. longum BB536, L. reuteri DSM17938, the multi-genus probiotic 
group, B. lactis Bb-12 OR B94 and L. rhamnosus LGG ATTC53103. However, the ORs of B. 
longum 35,624 + L. rhamnosus GG, L. rhamnosus LGG ATTC 53103, the multi-genus probi-
otic group and B. longum BB536 showed a wide CrI that included one (zero on the log 
scale). On the other hand, the ORs of B. lactis Bb-12 OR B94, based on four trials 
[39,45,55,69] with 355 infants, and L. reuteri DSM17938, based on four RCTs [36,46,48,56] 
with 631 infants, indicate that these treatments were associated with a reduced risk of any-
stage NEC in non-exclusively HM-fed preterm infants. Only B. lactis Bb-12 OR B94 was 
significantly associated with a reduced risk of stage ≥ 2 NEC, since one RCT evaluating L. 
reuteri DSM17938 also included stage 1 NEC [46]. 
Among treatments associated with much certainty with a reduced risk of NEC in 
both feeding sub-populations, we found a discrepancy in the relative effect size of B. lactis 
Bb-12 OR B94 in favor of exclusively HM-fed infants, although there was some overlap in 
the 95% CrIs (OR 0.04 with 95% CrI <0.01–0.49 vs. OR 0.32 with 95% CrI 0.10–0.96). 
4. Discussion 
To our knowledge, this is the first comprehensive and updated review of available 
literature regarding probiotic supplementation for prevention of NEC according to feed-
ing type. 
Fifty-one RCTs including data about over 10,000 infants were included in our sys-
tematic review. Outcome data according to feeding type were available for 31 RCTs in-
cluding over 4550 infants; only eight out of 29 probiotic treatments were studied in both 
exclusively and non-exclusively HM-fed infants. 
Some differences were observed between exclusively HM-fed vs. non-exclusively 
HM-fed infants. Based on available data and on both direct and indirect evidence, B. lactis 
Bb-12/B94 was associated with a reduced risk of stage ≥ 2 NEC both in exclusively HM- 
and non-exclusively HM-fed preterm infants, with a discrepancy in the relative effect size 
in favor of patients fed exclusively HM. B. bifidum + B. infantis + B. longum + L. acidophilus, 
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treatments associated with much certainty with a re uced risk of NEC in both
feeding sub-populations, we found a discrepancy in the relative effect size of B. lactis Bb-12
OR B94 in favor of exclusively HM-fed infants, although there was some overlap in the
95% CrIs (OR 0.04 with 95% CrI <0.01–0.49 vs. OR 0.32 with 95% CrI 0.10–0.96).
4. Discussion
To our knowledge, this is the first comprehensive and updated review o availab e
literature regarding probiotic supplem n at on for prevention of NEC according to feeding
type.
Fifty-one RCTs including data about over 10,000 infants were included in our system-
atic review. Outcome ata according to feeding type were available for 31 RCTs including
over 4550 infants; only eight out of 29 probiotic treatments were studied in both exclusively
and non-exclusively HM-fed infants.
Some differences were obs rved between exclusively HM-fed vs. non- xclusively
HM-fed infants. Based on available data an o both direct and indirect evidence, B. lactis
Bb-12/B94 was associated with a reduced risk of stage ≥ 2 NEC both in exclusively HM-
and non-exclusively HM-fed preterm infants, with a discrepancy in the relative effect size
in favor of patients fed exclusively HM. B. bifidum + B. infantis + B. longum + L. acidophilus,
B. infantis ATCC15697 + L. acidophilus ATCC4356 and B. longum R00175 + L. helveticus
R0052 + L. rhamnosus R0011 + Sa. boulardii CNCM-I-107 were also efficacious in exclusively
HM-fed infants. L. reuteri DSM17938 was associated with a reduced risk of stage ≥ 2 NEC
in exclusively HM-fed preterm infants and with a reduced risk of NEC at any stage in
non-exclusively HM-fed infants.
The results of our main analysis, performed regardless of infants’ feeding character-
istics, were only partially overlapping with the strain-specific NMA performed by the
ESPGHAN working group [16] since we included different and updated RCTs, some of
which evaluated new probiotic treatments [33,36,40,43,44,46,48,50,57,73,76]. Furthermore,
we did not include studies where probiotics were used together with other products [79,80]
and we focused on RCTs for which outcome data according to feeding type were available.
Recently, an NMA focused on the differential performance of multi-strain vs. single-
strain probiotics in reducing mortality and morbidity in preterm infants was published [18].
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The results of our main analysis confirm the efficacy of some interventions highlighted by
that paper, as the authors found that combinations of one or more Lactobacillus spp. and
one or more Bifidobacterium spp., Bifidobacterium lactis and Lactobacillus reuteri significantly
reduced severe NEC. However, some differences should be acknowledged. We chose to
identify probiotics at a higher taxonomic level and to group probiotic treatments differently;
moreover, included RCTs reporting on NEC are not completely overlapping.
Beyond probiotics’ efficacy, safety issues and possible probiotic side effects should also
be considered when choosing a probiotic product to be administered to preterm infants. In
this respect, the ESPGHAN panel on probiotics and preterm infants has recently issued a
conditional recommendation not to provide probiotic strains that produce D-lactate (i.e.,
L. reuteri DSM17938 or L. acidophilus NCO1748), as their potential risks or safety have not
been adequately studied in preterm infants and remain uncertain.
Some limitations of the present paper need to be acknowledged: both for the overall
population and for the subgroup population for which feeding data were available, the
number of probiotic treatments was considerable, most of the treatments were only evalu-
ated in one or two trials and only few strains were tested in at least four RCTs. As a result,
most probiotic interventions were evaluated in small experimental populations. To cope
with network sparseness and potential instability, we chose to group probiotic interventions
into treatment categories according to probiotics’ characteristics. Furthermore, the available
information on the highest-risk infants, such as those with extremely low birth weight
(ELBW) or intrauterine growth retardation, was limited: actually, only five [28,50,54,57,70]
of the 51 included studies included ELBW infants, and only three [28,57,70] studies reported
outcome in ELBW infants according to feeding type.
As for study quality, the evidence base was frequently dependent on many studies
with an unclear risk of bias for the various domains, with 12 studies having a high risk
of bias in at least one domain. Of note, most of the studies with a high risk of bias did
not contribute to the significant probiotic interventions. Most of the original RCTs did
not report NEC as a primary outcome and appeared to be underpowered. Therefore, the
generalizability and clinical applicability of our results require further confirmation.
5. Conclusions
We aimed to provide an overview of all published evidence on the use of probiotics
for prevention of NEC in preterm infants according to infant feeding characteristics.
Some interesting preliminary results were produced. Nonetheless, these results must
be interpreted in light of some limitations, as most probiotic strains were studied few times
and in small experimental populations. Therefore, the available data did not allow to pro-
vide strong recommendations on the most promising probiotic intervention(s) and to clarify
the relationship between NEC prevention and type of feeding in preterm infants receiving
probiotics. There is a need for adequately powered studies on probiotic supplementation in
preterm infants describing in greater detail the feeding characteristics of included infants,
with the aim of limiting potential confounding factors or assessing the role of potential
effect modifiers (i.e., percentage of MOM, duration of exclusive MOM, characteristics of
HM fortification, etc.). To overcome the impracticability of randomizing preterm infants
according to type of feeding, it appears reasonable to restrict inclusion criteria to infants fed
homogeneously (MOM, DHM or formula). Moreover, stringent controls on the production
of probiotics and attention to correct product identification at the highest taxonomic level
are needed not only for research purposes but also for clinical implementation.
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Appendix A Supplementary Statistical Methods
Network meta-analysis (NMA) is a technique that allows pairwise comparisons, even
when pairs of treatments have not been compared head-to-head in the same trial, relying
on the assumption of transitivity to estimate indirect treatment effects. We opted for a
random-effects model to incorporate the assumption that effect sizes were sampled from
a “population” of effect sizes, as the benefit of random-effects models when compared
to fixed-effect models is the ability to generalize their results to a broader “universe” of
studies [81,82].
We used arm-level data, binomial likelihood and logit link function and accounted
for the correlations induced by multi-arm studies by employing multivariate distributions.
We used vague zero-mean normal priors for the treatment effects, whereas, due to the
presence of small trials with no events in either arm (zero cells), we used an empirical
“semi-objective” “pharma-control” prior on the common between-study heterogeneity
variance [83,84]. Because some treatments only appeared in single trials with a zero cell,
we also used a “treatment arm” continuity correction accounting for potential group ratio
unbalance and centered around 0.5 [85].
All estimates were based on 600,000 iterations on three chains after a burn-in period of
50,000 runs. Convergence was ensured by visual inspection of the chains and considering
the Brooks–Gelman–Rubin diagnostic [86]. Trials with zero cells in both arms (no events)
were excluded from the primary network meta-analysis of odds ratios (Supplemental
Table S2-Supplementary Content), because such studies do not provide any indication
of either the direction or magnitude of the relative treatment effect. For this reason, a
sensitivity analysis was performed, re-running the network meta-analysis by using the
arcsine difference as a summary measure of treatment effects, which allowed incorporating
evidence from double-zero trials without requiring continuity corrections or the assignment
of informative prior distributions [87].
To check for consistency (i.e., agreement between direct evidence on a pairwise contrast
and indirect evidence from other contrasts), an “inconsistency model” (unrelated mean-
effects model) was built, in which consistency constraints were removed. This model is
equivalent to having separate meta-analyses for every comparison with a common variance
parameter. By plotting the posterior mean deviances of the individual trial arms from the
two models, we were able to assess possible inconsistency in the network [88]. However, it
should be recognized that tests for inconsistency are underpowered and can fail to detect
sources of inconsistencies [89].
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